Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors
文献类型：期刊论文
| 作者 | Lai, Meng-zhen2,3; Song, Pei-ran1,3,4; Dou, Dou5; Diao, Yan-yan5; Tong, Lin-jiang1,3; Zhang, Tao1,3,4; Xie, Hua1,3 ; Li, Hong-lin5; Ding, Jian1,3,4
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2020-03-01 |
| 卷号 | 41期号:3页码:415-422 |
| 关键词 | B cell receptor Bruton's tyrosine kinase ibrutinib small-molecule inhibitor B cell malignancies |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-019-0250-8 |
| 通讯作者 | Xie, Hua(hxie@simm.ac.cn) ; Li, Hong-lin(hlli@ecust.edu.cn) ; Ding, Jian(jding@simm.ac.cn) |
| 英文摘要 | Bruton's tyrosine kinase (BTK) is a key component of the B cell receptor (BCR) signaling pathway and plays a crucial role in B cell malignancies and autoimmune disorders; thus, it is an attractive target for the treatment of B cell related diseases. Here, we evaluated the BTK inhibitory activity of a series of pyrimido[4,5-d][1,3]oxazin-2-one derivatives. Combining this evaluation with structure-activity relationship (SAR) analysis, we found that compound 2 exhibited potent BTK kinase inhibitory activity, with an IC50 of 7 nM. This derivative markedly inhibited BTK activation in TMD8 B cell lymphoma cells and thus inhibited the in vitro growth of the cells. Further studies revealed that compound 2 dose dependently arrested TMD8 cells at G(1) phase, accompanied by decreased levels of Rb, phosphorylated Rb, and cyclin D1. Moreover, following treatment with compound 2, TMD8 cells underwent apoptosis associated with PARP and caspase 3 cleavage. Interestingly, the results of the kinase activity assay on a small panel of 35 kinases showed that the kinase selectivity of compound 2 was superior to that of the first-generation inhibitor ibrutinib, suggesting that compound 2 could be a second-generation inhibitor of BTK. In conclusion, we identified a potent and highly selective BTK inhibitor worthy of further development. |
| WOS关键词 | ACALABRUTINIB ACP-196 ; IBRUTINIB ; BTK ; RECEPTOR ; RESISTANCE ; RESPONSES ; CELLS |
| 资助项目 | National Key Research and Development Program[2016YFA0502304] ; Special Program for Applied Research on Super Computation of the NSFC-Guangdong Joint Fund (the second phase)[U1501501] ; Fundamental Research Funds for the Central Universities |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000514159600013 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/281222]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xie, Hua; Li, Hong-lin; Ding, Jian |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Nanchang Univ, Sch Pharm, Nanchang 330006, Jiangxi, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China 5.East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China |
| 推荐引用方式 GB/T 7714 | Lai, Meng-zhen,Song, Pei-ran,Dou, Dou,et al. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors[J]. ACTA PHARMACOLOGICA SINICA,2020,41(3):415-422. |
| APA | Lai, Meng-zhen.,Song, Pei-ran.,Dou, Dou.,Diao, Yan-yan.,Tong, Lin-jiang.,...&Ding, Jian.(2020).Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.ACTA PHARMACOLOGICA SINICA,41(3),415-422. |
| MLA | Lai, Meng-zhen,et al."Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors".ACTA PHARMACOLOGICA SINICA 41.3(2020):415-422. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。